Dr. Von-Mehren is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Philadelphia, PA 19111Phone+1 215-728-2500Fax+1 215-728-3639
Summary
- Dr. Margaret von Mehren is an oncologist in Philadelphia, PA at Fox Chase Cancer Center in the Temple University Health System. She received her medical degree from Albany Medical College and has been in practice 28 years. She specializes in management of sarcoma with a special emphasis on Gastrointestinal Stromal Tumors.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
NYU Grossman School of MedicineResidency, Internal Medicine, 1989 - 1992
Albany Medical CollegeClass of 1989
Certifications & Licensure
NJ State Medical License 2021 - 2025
PA State Medical License 1992 - 2024
NY State Medical License 1990 - 1992- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1] Start of enrollment: 2022 Aug 01
Roles: Contact
Publications & Presentations
PubMed
- 2 citationsDataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR).Jason L Hornick, Fleur Webster, Angelo Paolo Dei Tos, Chris Hemmings, Markku Miettinen
Histopathology. 2023-02-01 - 5 citationsPatient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INV...Patrick Schöffski, Suzanne George, Michael C Heinrich, John R Zalcberg, Sebastian Bauer
BMC Cancer. 2022-12-13 - 36 citationsRipretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.Sebastian Bauer, Robin L Jones, Jean-Yves Blay, Hans Gelderblom, Suzanne George
Journal of Clinical Oncology. 2022-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
